Market news

Immatics (IMTX) said Tuesday that it has agreed to sell 12,945,916 ordinary shares at $8.69 each, an

Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death) occurring more slowly than originally modeledCompany plans to proceed directly to a streamlined final analysis for the primary endpoint, PFS, while strengthening power for the secondary endpoint, OS, to enhance the commercial product profile SUP

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

The treatment eliminated a boy's tumors with a single infusion.

Houston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain. The three presentations will include: Phase 1b data from anzu-cel, the Company’s lead PRAME cell th